119 related articles for article (PubMed ID: 1289146)
1. Plasminogen activator in human tears.
Stevens JD; Marshall JM; Benjamin L; Cederholm-Williams SA; Bron AJ
Eye (Lond); 1992; 6 ( Pt 6)():653-8. PubMed ID: 1289146
[TBL] [Abstract][Full Text] [Related]
2. Plasminogen activators in human nasal polyps and mucosa.
Larsen K; de Maat MP; Jespersen J
Rhinology; 1997 Dec; 35(4):175-7. PubMed ID: 9532638
[TBL] [Abstract][Full Text] [Related]
3. Protein and messenger RNA levels of plasminogen activators and inhibitors analyzed in 22 human tumor cell lines.
Quax PH; van Leeuwen RT; Verspaget HW; Verheijen JH
Cancer Res; 1990 Mar; 50(5):1488-94. PubMed ID: 2105839
[TBL] [Abstract][Full Text] [Related]
4. Comparative study of plasminogen activators in cancers and normal mucosae of human urinary bladder.
Hasui Y; Suzumiya J; Marutsuka K; Sumiyoshi A; Hashida S; Ishikawa E
Cancer Res; 1989 Feb; 49(4):1067-70. PubMed ID: 2492205
[TBL] [Abstract][Full Text] [Related]
5. Plasminogen activator content of human tumor and adjacent normal tissue measured with fibrin and non-fibrin assays.
Camiolo SM; Greco WR
Cancer Res; 1986 Apr; 46(4 Pt 1):1788-94. PubMed ID: 3081257
[TBL] [Abstract][Full Text] [Related]
6. Tissue plasminogen activator activity in human aqueous humor.
Smalley DM; Fitzgerald JE; Taylor DM; Cone RE; O'Rourke J
Invest Ophthalmol Vis Sci; 1994 Jan; 35(1):48-53. PubMed ID: 8300363
[TBL] [Abstract][Full Text] [Related]
7. Components of the plasminogen activation system in uveal melanoma--a clinico-pathological study.
De Vries TJ; Mooy CM; Van Balken MR; Luyten GP; Quax PH; Verspaget HW; Weidle UH; Ruiter DJ; Van Muijen GN
J Pathol; 1995 Jan; 175(1):59-67. PubMed ID: 7891228
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1, and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multicenter basis.
Kim SJ; Shiba E; Kobayashi T; Yayoi E; Furukawa J; Takatsuka Y; Shin E; Koyama H; Inaji H; Takai S
Clin Cancer Res; 1998 Jan; 4(1):177-82. PubMed ID: 9516968
[TBL] [Abstract][Full Text] [Related]
9. Enzyme-linked immunosorbent assay for human urokinase-type plasminogen activator and its proenzyme using a combination of monoclonal and polyclonal antibodies.
Nielsen LS; Grøndahl-Hansen J; Andreasen PA; Skriver L; Zeuthen J; Danø K
J Immunoassay; 1986; 7(3):209-28. PubMed ID: 3091639
[TBL] [Abstract][Full Text] [Related]
10. Plasminogen activator: the identification of an additional proteinase at the outer acrosomal membrane of human and boar spermatozoa.
Smokovitis A; Kokolis N; Taitzoglou I; Rekkas C
Int J Fertil; 1992; 37(5):308-14. PubMed ID: 1358844
[TBL] [Abstract][Full Text] [Related]
11. Changes in the fibrinolytic components of cultured human umbilical vein endothelial cells induced by endotoxin, tumor necrosis factor-alpha and interleukin-1alpha.
Orbe J; Chordá C; Montes R; Páramo JA
Haematologica; 1999 Apr; 84(4):306-11. PubMed ID: 10190943
[TBL] [Abstract][Full Text] [Related]
12. Factors involved in the plasminogen activation system in human breast tumours.
Damjanovich L; Turzó C; Adány R
Thromb Haemost; 1994 Jun; 71(6):684-91. PubMed ID: 7974332
[TBL] [Abstract][Full Text] [Related]
13. Relationship of membrane-bound tissue type and urokinase type plasminogen activators in human breast cancers to estrogen and epidermal growth factor receptors.
Needham GK; Nicholson S; Angus B; Farndon JR; Harris AL
Cancer Res; 1988 Nov; 48(22):6603-7. PubMed ID: 3141047
[TBL] [Abstract][Full Text] [Related]
14. Growth factors, tissue and urokinase-type plasminogen activators in venous ulcers.
Lagattolla NR; Stacey MC; Burnand KG; Gaffney PG
Ann Cardiol Angeiol (Paris); 1995; 44(6):299-303. PubMed ID: 7574362
[TBL] [Abstract][Full Text] [Related]
15. Immunological characterization of plasminogen activator activities in human tissues and body fluids.
Rijken DC; Wijngaards G; Welbergen J
J Lab Clin Med; 1981 Apr; 97(4):477-86. PubMed ID: 6782183
[TBL] [Abstract][Full Text] [Related]
16. Inhibition in purified systems and in human plasma of chimaeric plasminogen activators consisting of the NH2-terminal region of tissue-type plasminogen activator and the COOH-terminal region of urokinase-type plasminogen activator.
Lijnen HR; Nelles L; Van Hoef B; De Cock F; Collen D
Thromb Haemost; 1988 Oct; 60(2):247-50. PubMed ID: 3146141
[TBL] [Abstract][Full Text] [Related]
17. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
Collen D; De Cock F; Demarsin E; Lijnen HR; Stump DC
Thromb Haemost; 1986 Aug; 56(1):35-9. PubMed ID: 3095946
[TBL] [Abstract][Full Text] [Related]
18. Measurement of urokinase-type plasminogen activator (u-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies.
Darras V; Thienpont M; Stump DC; Collen D
Thromb Haemost; 1986 Dec; 56(3):411-4. PubMed ID: 3105111
[TBL] [Abstract][Full Text] [Related]
19. Possible role of the plasminogen activation system in human subfertility.
Ebisch IM; Steegers-Theunissen RP; Sweep FC; Zielhuis GA; Geurts-Moespot A; Thomas CM
Fertil Steril; 2007 Mar; 87(3):619-26. PubMed ID: 17123524
[TBL] [Abstract][Full Text] [Related]
20. Assay method for single-chain urokinase-type plasminogen activator.
Matsuo O; Ueshima S; Okada K; Fukao H; Ohgaki M; Watanabe R; Arimura H
Hematol Pathol; 1989; 3(3):137-42. PubMed ID: 2531734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
